Back to search
Search Results 1-10 of 28 clinical trials found.
In the TRACE COVID-19 study, we are investigating whether COVID-19 infection causes any changes in heart electrocardiogram (ECG) tracings that can be detected by wearable devices such as the Apple Watch. The goal is to determine whether the ECG can detect COVID-19 infection before the onset of any symptoms.
Study participants will be asked to use their Apple Watch to obtain their ECG and fill out a very short survey daily. All data are de-identified (anonymized).
For more details and to enroll in the study, please go to the study website: http://tracecovid19study.com
The main goal of this study is to evaluate and help predict decline in at risk populations with COVID-19 or those exposed to COVID-19+ individuals who could benefit from having a remote monitoring system in their homes to provide valuable information to their care teams.
ACTIV-1 IM is a master protocol designed to evaluate multiple investigational agents for the
treatment of moderately or severely ill patients infected with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). The research objectives are to evaluate each agent with
respect to speed of recovery, mortality, illness severity, and hospital resource utilization.
Each agent will be evaluated as add-on therapy to the standard of care (SoC) in use at the
local clinics, including remdesivir (provided). The SoC may change during the course of the
study based on other research findings. Comparisons of the agents among themselves is not a
The study population corresponds to moderately and severely ill patients infected with the
coronavirus disease 2019 (COVID-19) virus. Recruitment will target patients already
hospitalized for treatment of COVID-19 infection as well as patients being treated for
This is a randomized, open label, adaptive platform trial to compare the effectiveness of
antithrombotic strategies for prevention of adverse outcomes in COVID-19 positive inpatients
Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the
efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults
with polymerase chain reaction (PCR)-Confirmed COVID-19.
Drug studies often look at the effect one or two drugs have on a medical condition, and
involve one company. There is currently an urgent need for one study to efficiently test
multiple drugs from more than one company, in people who have tested positive for COVID-19
but who do not currently need hospitalization. This could help prevent disease progression to
more serious symptoms and complications, and spread of COVID-19 in the community.
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in
outpatients. Participants in the study will be treated with either a study drug or with
This study collects blood samples, medical information, and medical images from patients who
are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus
that causes the disease called COVID-19. Collecting blood samples, medical information, and
medical images may help researchers determine how COVID-19 affects the outcomes of patients
undergoing cancer treatment and how having cancer affects COVID-19.
This study will provide access to investigational anti-SARS-CoV-2 human convalescent plasma
for pediatric patients with underlying medical conditions (cardiovascular disease, lung
disease, immunosuppression) who are either infected with SARS-CoV-2 or who have had a
high-risk exposure. Study participants will be transfused once with compatible convalescent
plasma obtained from an individual who has recovered from documented infection with
SARS-CoV-2. Safety information and pharmacokinetic data will be collected.
Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development
phases (Phase 2 and Phase 3).
The overarching goal of this project is to confirm or refute the role of passive immunization
as a safe and efficacious therapy in preventing the progression from mild to severe/critical
COVID-19 illness and to understand the immunologic kinetics of anti-SARS-CoV-2 antibodies
after passive immunization.The primary objective is to determine the efficacy and safety of a
single dose of convalescent plasma (CP) for preventing the progression from mild to severe
COVID-19 illness. The secondary objective is to characterize the immunologic response to CP
This study will adults presenting to the emergency department (ED) with mild, symptomatic,
laboratory-confirmed COVID-19 illness, who are at high risk for progression to
severe/critical illness, but who are clinically stable for outpatient management at
Back to search
Learn more about myUCLAhealth